Drug Detail:Lanreotide (Lanreotide)
Drug Class: Somatostatin and somatostatin analogs
Lanreotide Levels and Effects while Breastfeeding
Summary of Use during Lactation
The excretion of lanreotide into breastmilk has not been studied. However, because it has a high molecular weight of 1096 daltons it is likely to be poorly excreted into breastmilk and it is a peptide that is likely digested in the infant's gastrointestinal tract, so it is unlikely to reach the clinically important levels in infant serum. Lanreotide has been given by injection to newborn infants with congenital hyperinsulinemia; reversible mild elevation of liver enzymes occurred in some infants.[1] The manufacturer states that women should not breastfeed during treatment with depot lanreotide and for 6 months following the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
A woman with acromegaly was treated with lanreotide Autogel 120 mg monthly, cabergoline 2 mg weekly and pegvisomant 80 mg weekly. She breastfed (extent not stated) her infant and they were followed for 12 years. Her child had normal growth and development.[2]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Octreotide
References
- 1.
-
van der Steen I, van Albada ME, Mohnike K, et al. A multicenter experience with long-acting somatostatin analogues in patients with congenital hyperinsulinism. Horm Res Paediatr. 2018;89:82–9. [PubMed: 29241206]
- 2.
-
Popescu AD, Carsote M, Valea A, et al. Approach of acromegaly during pregnancy. Diagnostics (Basel). 2022;12:2669. [PMC free article: PMC9689290] [PubMed: 36359512]
Substance Identification
Substance Name
Lanreotide
CAS Registry Number
108736-35-2
Drug Class
Breastfeeding
Lactation
Milk, Human
Hormones
Somatostatin Analogs and Derivatives
Antineoplastic Agents, Hormonal
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification